Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
This PHASE1 trial investigates Hormone Receptor Positive Malignant Neoplasm of Breast and is currently completed. Stemline Therapeutics, Inc. leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Dec 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stemline Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .